How to Fight Insurance Denials for Cardiac Devices and Procedures

Insurance denials for cardiac devices and procedures are frustratingly common—even when your cardiologist says the treatment could save your life. Implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT-D), transcatheter aortic valve replacement (TAVR), Watchman left atrial appendage closure, MitraClip, left ventricular assist devices (LVADs), catheter ablations for atrial fibrillation or ventricular tachycardia, and advanced cardiac imaging all face intense scrutiny. Insurers rely on rigid checklists from Medicare National Coverage Determinations (NCDs) and specialty society guidelines, then deny claims for missing documentation, alleged timing violations, or outdated beliefs about what's "experimental." This guide walks you through the specific denial reasons you'll encounter, the citations insurers actually respect, and concrete steps to build a winning appeal.

Why Insurers Deny Cardiac Devices and Procedures

1. "Guideline-directed medical therapy (GDMT) not optimized or trial duration insufficient"

For primary-prevention ICDs and CRT devices, Medicare NCD 20.4 requires at least 3 months of optimized medical therapy—and at least 40 days since your heart attack (MI) or 90 days since your last revascularization (stent or bypass). Insurers deny if your records don't explicitly list each medication with dose and start date, or if your ejection fraction was measured "too soon" after a cardiac event.

2. "Procedure is experimental or investigational for your risk level"

TAVR denials frequently cite "low surgical risk is not FDA-approved" or "not medically necessary"—even though the FDA approved TAVR for low-risk severe aortic stenosis in 2019 based on PARTNER 3 and Evolut Low Risk trials, and the 2020 ACC/AHA Valvular Heart Disease guideline (updated 2023) made TAVR a Class 1 recommendation across all surgical risk strata. Similarly, MitraClip for functional (secondary) mitral regurgitation is often denied as "investigational," despite Medicare NCD 20.34 covering it when patients meet COAPT trial criteria.

3. "Heart Team evaluation or shared decision-making not documented"

TAVR (NCD 20.32) requires a multidisciplinary Heart Team including two independent cardiac surgeons who each sign off on your suitability. Watchman left atrial appendage closure (NCD 20.33) and primary-prevention ICDs (NCD 20.4) require formal shared decision-making (SDM) with a non-implanting physician. If your medical record doesn't explicitly document these conversations with signatures and dates, insurers auto-deny.

4. "Alternative therapy not tried or contraindication not documented"

Watchman denials often say "patient can tolerate anticoagulation" if your chart doesn't list specific bleeding events, renal insufficiency with CrCl thresholds, fall risk scores, or documented refusal. Atrial fibrillation ablation denials may claim "failed antiarrhythmic drug trial required," ignoring the 2023 AFib guideline upgrade that made catheter ablation a Class 1 first-line option for symptomatic paroxysmal AFib—no drug trial needed.

5. "Imaging or diagnostic criteria not met"

LVEF measurement method matters: insurers prefer Simpson's biplane echocardiography or cardiac MRI with clear report dates. CRT-D denials hinge on QRS duration ≥150 ms and left bundle branch block (LBBB) morphology for Class I indication. TAVR requires documented severe aortic stenosis: mean gradient ≥40 mmHg and aortic valve area <1.0 cm². If any number is missing or borderline, expect a denial.

The Citations Insurers Respect

When you appeal, reference these by name and year. Do not let your doctor write "guidelines support this"—be specific.

Medicare National Coverage Determinations (NCDs)

• NCD 20.4 (Implantable Automatic Defibrillators, revised 2018): Primary prevention ICD coverage for LVEF ≤35% after ≥3 months GDMT, ≥40 days post-MI or ≥90 days post-revascularization. Requires shared decision-making.
• NCD 20.32 (Transcatheter Aortic Valve Replacement, 2019 expansion): Covers TAVR for symptomatic severe aortic stenosis across all surgical risk levels when Heart Team evaluation includes two cardiac surgeons and procedure is performed at approved centers.
• NCD 20.33 (Percutaneous Left Atrial Appendage Closure, 2016): Covers Watchman for nonvalvular AFib patients with CHA₂DS₂-VASc ≥3 (men) or ≥4 (women) and appropriate rationale to seek alternative to long-term anticoagulation. Requires shared decision-making with non-implanting physician.
• NCD 20.34 (Transcatheter Mitral Valve Repair, 2014): Covers MitraClip for symptomatic moderate-to-severe or severe primary mitral regurgitation when surgery is prohibited or high-risk, and for select secondary MR patients meeting COAPT trial phenotype.

Clinical Practice Guidelines

• 2017 ACC/AHA/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (updated 2018): Class I recommendation for ICD in LVEF ≤35%, NYHA II-III, ischemic or nonischemic cardiomyopathy on GDMT.
• 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease (focused update 2023): Class 1 recommendation for TAVR in symptomatic severe AS across low, intermediate, and high surgical risk; detailed Heart Team and shared decision-making requirements.
• 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: Upgraded catheter ablation to Class 1 first-line therapy for symptomatic paroxysmal AFib, removing the prior requirement for failed antiarrhythmic drug trial.
• 2021 ESC Guidelines on Cardiac Pacing and CRT: Class I indication for CRT-D when LVEF ≤35%, sinus rhythm, LBBB with QRS ≥150 ms, and NYHA II–IV on GDMT.

Pivotal Clinical Trials

• PARTNER 3 (NEJM 2019): Demonstrated TAVR superiority to surgery in low-risk severe AS.
• Evolut Low Risk (NEJM 2019): Showed TAVR non-inferiority to surgery in low-risk AS, leading to FDA approval.
• COAPT (NEJM 2018): Established MitraClip efficacy in secondary (functional) mitral regurgitation for patients meeting specific echo and heart failure criteria (LVEF 20–50%, LV end-systolic diameter ≤70 mm, proportionate MR).
• PREVAIL and PROTECT AF (JAMA 2014, Circulation 2013): Trials supporting Watchman LAA closure for stroke prevention in nonvalvular AFib with contraindication or challenge to long-term anticoagulation.
• EARLY-AF (JAMA Cardiology 2021) and STOP-AF First (NEJM 2021): Demonstrated catheter ablation superiority to antiarrhythmic drugs as first-line therapy in paroxysmal AFib.

How to Argue Against Each Denial Reason

"GDMT not optimized or trial duration insufficient"

Concrete steps:

1. Create a GDMT timeline table with four columns: medication name, dose, start date, and current duration. Include all pillars: ACE-inhibitor or ARB or ARNI (sacubitril/valsartan), beta-blocker, mineralocorticoid receptor antagonist (spironolactone or eplerenone), and SGLT2 inhibitor (if applicable).

2. Document why any missing medication is contraindicated or not tolerated. If you're not on spironolactone, note hyperkalemia or renal dysfunction. If you're not on ARNI, note cost or prior angioedema.

3. Provide dated echocardiograms or MRIs showing LVEF ≤35% after the 3-month GDMT period.

4. Confirm timing from cardiac events: If you had a heart attack, count forward 40 days and attach the discharge summary. If you had PCI or CABG, count forward 90 days.

5. Cite NCD 20.4 explicitly: "Medicare NCD 20.4 (2018 revision) requires ≥3 months of GDMT, ≥40 days post-MI, and ≥90 days post-revascularization. All criteria are met as documented."

6. Attach the shared decision-making note (required under NCD 20.4) showing you and a physician discussed ICD risks, benefits, and alternatives.

"Procedure is experimental or investigational for your risk level"

For TAVR in low or intermediate surgical risk:

1. State the FDA approval clearly: "TAVR received FDA approval for low surgical risk in June 2019 based on PARTNER 3 and Evolut Low Risk trials published in NEJM 2019."

2. Quote the 2023 ACC/AHA Valvular Heart Disease guideline update verbatim: TAVR is a Class 1 recommendation for symptomatic severe AS in patients at low, intermediate, or high surgical risk.

3. Include your STS-PROM score (Society of Thoracic Surgeons Predicted Risk of Mortality) from the Heart Team evaluation. Even a score <4% (low risk) now supports TAVR.

4. Attach the Heart Team documentation showing two independent cardiac surgeons evaluated you and signed suitability letters (NCD 20.32 requirement).

For MitraClip in secondary (functional) MR:

1. Cite NCD 20.34 and explain that Medicare covers MitraClip for secondary MR when patients meet COAPT trial eligibility: LVEF 20–50%, LV end-systolic diameter ≤70 mm, moderate-to-severe or severe MR that is "proportionate" to LV size, NYHA II–IV despite GDMT.

2. Provide echo measurements matching COAPT criteria: effective regurgitant orifice area (EROA), regurgitant volume, LV dimensions.

3. Emphasize you are not a candidate for surgical repair due to frailty, comorbidities, or prohibitive surgical risk per Heart Team.

4. Reference COAPT trial results (NEJM 2018): 47% reduction in heart failure hospitalization, mortality benefit at 2 years.

"Heart Team evaluation or shared decision-making not documented"

Concrete steps:

1. Request a formal addendum from your cardiologist, cardiac surgeon, or electrophysiologist documenting the multidisciplinary discussion. For TAVR, it must name the interventional cardiologist, imaging cardiologist, cardiac anesthesiologist, and two cardiac surgeons. Each surgeon must independently document your candidacy.

2. For Watchman or primary-prevention ICD, schedule a SDM visit with a non-implanting physician (not the electrophysiologist or interventional cardiologist doing the procedure). The note must state: "Risks, benefits, and alternatives discussed. Patient demonstrates understanding. Patient chooses to proceed."

3. Cite the NCD: "NCD 20.32 mandates Heart Team evaluation including two cardiac surgeons. Documentation attached from Dr. [Surgeon A] and Dr. [Surgeon B], each confirming candidacy."

4. Submit dated, signed consultation notes as exhibits with your appeal letter. Unsigned or undated notes are routinely rejected.

"Alternative therapy not tried or contraindication not documented"

For Watchman when insurer says "try a DOAC":

1. List every contraindication explicitly: prior intracranial hemorrhage (date), GI bleed on anticoagulation (date and endoscopy report), CrCl <30 mL/min (labs with date), fall risk (STEADI score or gait/balance assessment), patient refusal after informed discussion (SDM note).

2. Calculate and state your CHA₂DS₂-VASc score. NCD 20.33 requires ≥3 (men) or ≥4 (women).

3. Cite NCD 20.33: "Coverage is provided for patients with appropriate rationale to seek non-pharmacologic alternative to oral anticoagulation. [Patient name] has documented contraindication [X] and SDM note attached."

4. Provide the SDM note from a non-implanting cardiologist confirming discussion of Watchman vs. lifelong anticoagulation risks.

For AFib ablation when insurer demands failed drug trial:

1. Quote the 2023 AFib guideline directly: "Catheter ablation is now a Class 1 recommendation for initial rhythm-control therapy in patients with symptomatic paroxysmal AFib (no prior antiarrhythmic drug trial required)."

2. Cite EARLY-AF (JAMA Cardiology 2021) and STOP-AF First (NEJM 2021): both showed ablation superiority to drugs as first-line therapy.

3. Document symptom burden: palpitations, dyspnea, reduced exercise tolerance, emergency visits for AFib, quality-of-life impairment (AFEQT score if available).

4. If you did try a drug and failed or had side effects, document the medication name, dose, duration, and reason for discontinuation (ineffective, bradycardia, fatigue, etc.).

"Imaging or diagnostic criteria not met"

For ICD/CRT denials citing LVEF or QRS issues:

1. Provide the full echocardiography or cardiac MRI report, including: LVEF percentage, measurement method (Simpson's biplane strongly preferred), report date, reading cardiologist name.

2. For CRT-D, provide a 12-lead ECG showing QRS duration in milliseconds and confirming LBBB morphology. Class I indication requires QRS ≥150 ms with LBBB; Class IIa allows ≥150 ms with non-LBBB or 120–149 ms with LBBB.

3. If LVEF improved slightly (e.g., from 25% to 38%) after GDMT, emphasize persistent symptoms (NYHA class II–III), arrhythmia burden, or scar on cardiac MRI (late gadolinium enhancement) indicating ongoing risk.

4. Cite the 2017 ACC/AHA/HRS Ventricular Arrhythmia guideline and the specific Class I or IIa indication your patient meets.

For TAVR denials citing borderline AS severity:

1. Provide the full echo Doppler report with: peak aortic jet velocity (m/s), mean transvalvular gradient (mmHg), and aortic valve area (cm²) by continuity equation.

2. Confirm "severe" AS thresholds: mean gradient ≥40 mmHg, AVA ≤1.0 cm², peak velocity ≥4.0 m/s. If any single measure is borderline but others are clearly severe, highlight concordance or request dobutamine stress echo if low-flow suspected.

3. Document symptoms: dyspnea, angina, syncope, heart failure exacerbations. Asymptomatic severe AS is typically not covered unless LVEF <50% or undergoing other cardiac surgery.

4. Attach the Heart Team letter and STS-PROM calculation.

What We Do

We help patients and families draft physician-ready appeal letters for denied cardiac devices and procedures. Every letter is built on the specific NCDs, guidelines, and trial data insurers are contractually or regulatorily required to honor—NCD 20.4, 20.32, 20.33, and 20.34, the 2023 AFib guideline update, PARTNER 3, COAPT, and more. You provide your medical records and denial letter; we generate a structured appeal citing the exact policy language, clinical criteria, and evidence your cardiologist needs to overturn the denial. Our software is designed by clinicians who know that "medically necessary" means meeting specific, named criteria—not vague platitudes.

Sources

1. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 20.4: Implantable Automatic Defibrillators. Revised June 2018.

2. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 20.32: Transcatheter Aortic Valve Replacement (TAVR). Expanded May 2019.

3. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 20.33: Percutaneous Left Atrial Appendage (LAA) Closure Therapy. Effective February 2016.

4. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 20.34: Transcatheter Mitral Valve Repair (TMVR). Effective August 2014.

5. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation. 2018;138(13):e272-e391.

6. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. Focused Update 2023.

7. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1-e156.

8. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-3520.

9. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705. (PARTNER 3)

10. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1706-1715. (Evolut Low Risk)

11. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379(24):2307-2318. (COAPT)

12. Holmes DR Jr, Kar S, Price MJ, et al. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial. J Am Coll Cardiol. 2014;64(1):1-12.

13. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017;70(24):2964-2975.

14. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2021;384(4):305-315. (EARLY-AF)

15. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Engl J Med. 2021;384(4):316-324. (STOP-AF First)